About Release Tx
Release Tx is a company based in Geneve (Switzerland) founded in 2023. Release Tx has raised $3.88 million across 1 funding round. Release Tx offers products and services including Platform Technology. Release Tx operates in a competitive market with competitors including Impel NeuroPharma, CraniUS, Cognos Therapeutics, Cordance Medical and PassPort Technologies, among others.
- Headquarter Geneve, Switzerland
- SectorsHealthcare
- Email••••••••
- Website release-tx.com
- Social LinkedIn
- Total Equity Funding$3.88M (USD)
in 1 rounds
- Latest Funding Round$3.88M (USD), Seed
Aug 2024
Products & Services of Release Tx
Release Tx offers a comprehensive portfolio of products and services, including Platform Technology.
Technology for targeted delivery of proteins to treat CNS genetic disorders
Funding Insights of Release Tx
Release Tx has successfully raised a total of $3.88M through 1 strategic funding round. The most recent funding activity was a Seed round of $3.88 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3.88M
- Total Rounds 1
- Last Round Seed — $3.88M
- First Round $3.88M
(Aug 2024)
All 1 funding rounds of Release Tx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2024 | $3.88M | Seed | – | – | – |
People of Release Tx
1 people are tracked at Release Tx (1 in leadership).
| Name | Role | Group |
|---|---|---|
Thomas Mehrling | CEO | Leadership |
Complete people profiles for Release Tx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Release Tx
2 dated milestones of Release Tx across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Release Tx is founded.
- Funding First funding round of $3.9M.
Competitors of Release Tx
Release Tx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Impel NeuroPharma, CraniUS, Cognos Therapeutics, Cordance Medical and PassPort Technologies, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| impelnp.com | 2008 | Seattle, United States | $126.83M | 158 | Intranasal delivery technology for CNS diseases is developed. | |
| craniustherapeutics.com | 2021 | Baltimore, United States | $20.5M | – | Drug delivery systems for brain diseases and disorders are developed. | |
| cognosthx.com | 2015 | Los Angeles, United States | $5.75M | 13 | Cognos Therapeutics is focused on innovative neurological and oncological treatments. | |
| cordancemedical.com | 2018 | Mountain View, United States | – | – | Non-invasive ultrasound device for blood-brain barrier is developed. | |
| passport-tech.com | 2019 | San Diego, United States | – | – | Transdermal drug delivery systems are developed using microporation technology. | |
| bionxt.com | 2018 | Vancouver, Canada | – | 49 | Drug formulations and delivery systems for diseases are developed. | |
| nsgene.dk | 1999 | Ballerup, Denmark | $5.14M | – | Specializes in drug delivery systems and therapeutics for central nervous system diseases. | |
| palyonmedical.com | 2004 | New York, United States | $24M | – | Develops implantable drug delivery systems for central nervous system disorders. | |
| sinontx.com | 2015 | Durham, United States | – | – | Nanoparticle-based drug delivery platform for neurological diseases is developed. |
Detailed competitors of Release Tx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Release Tx
Complete news archive for Release Tx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Release Tx
10 companies that operate in the same segment as Release Tx (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Release Tx
Release Tx was founded in 2023 and raised its 1st funding round 1 year after it was founded.
Release Tx is headquartered in Geneve, Switzerland. It is registered at Geneve, Geneve, Switzerland.
Thomas Mehrling is the current CEO of Release Tx.
Release Tx is a funded company, having raised a total of $3.88M across 1 funding round to date. The company's 1st funding round was a Seed of $3.88M, raised on Aug 2024.
A versatile and retrievable cell macroencapsulation device is being engineered by Release Tx, founded in 2023 in Geneva, Switzerland. Therapeutic proteins are delivered through this device to address central nervous system hereditary diseases, with a primary focus on metachromatic leukodystrophy. Operations center on biotechnology innovations in the healthcare sector, targeting clinical applications for neurological conditions.
Release Tx's top competitors include Impel NeuroPharma, CraniUS and Cognos Therapeutics.
Release Tx offers Platform Technology.